Shots:

• The P-III study results involves assessing of Taltz in patients with moderate to severe plaque psoriasis for 5yrs.in addition to an extension study UNCOVER-1
• Collective results: 90%+ maintained skin clearance as measured by PASI 75; @264wks. PASI 75 (94.3); PASI 90 (81.8%); PASI 100 (46.6%)- presented at WCD with additional data of UNCOVER-3 study
• Taltz (80mg/ml- pre-filled syringe) is a mAb act by targeting IL-17A- being studied in 13 clinical studies in 17-000+ patients under Taltz clinical study program and is an approved therapy for moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

Ref: Eli Lilly | Image: Eli Lilly